Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner ...
Zacks.com on MSN1d
TSVT, BMY Discontinue Enrollment in Late-stage Abecma StudyTSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment ...
据了解，2seventy bio和其合作伙伴百时美施贵宝宣布，将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究，旨在评估Abecma与来那度胺联合治疗，以及来那度胺单药治疗的效果。两家公司表示，这一决定是在对该研究的商业理由进行彻底审查后做出的。
2seventy bio, Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback